FDA Determines Regulatory Review Period for Buphenyl Powder Patent Extension

Summary

The Food and Drug Administration has officially announced the regulatory review period for Buphenyl Powder, a human drug product, in response to a patent extension application submitted to the U.S. Patent and Trademark Office.